跳至主要内容
临床试验/NCT03902496
NCT03902496已完成不适用

Optical Treatment of Migraines Clinical Study

Avulux, Inc.2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年3月18日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
2
主要终点
Headache Impact Test (HIT-6) total score

研究概览

简要总结

The primary objective of this study is to evaluate the efficacy of the Avulux device in reducing the impact of migraine headaches as measured by improvement in Headache Impact Test (HIT-6TM) scores at three weeks when compared to a control/sham device.

详细描述

Avulux™ is intended to decrease the impact of headache and migraine on normal daily life and the ability to function, and reduce the frequency and severity of headache, in adult patients diagnosed with episodic migraine headache or chronic migraine.

Avulux™ consists of a pair of optical filters in the form of spectacle lenses, provided in standard spectacle frames or as clip-on units, coated with a thin film that effectively blocks light at specified wavelength ranges while minimizing distortion of the visible spectrum. The optical filters block a portion of the optical spectrum that is suspected to stimulate photophobic responses that trigger some, and exacerbate most, migraines.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

The active and sham lenses will have tints calibrated such that the optical density, that is the overall "darkness" of all study lenses, will be the same. All study lenses will appear to have the same overall light-blocking effect to study subjects.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient is 18 years or older
  • Patient is willing and able to provide written informed consent
  • Patient is willing and able to complete all scheduled study visits
  • Diagnosis of migraine, based on the following primary headache characteristics:
  • At least 5 attacks fulfilling criteria b-d:
  • Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
  • Headache has at least two of the following characteristics:
  • unilateral location
  • pulsating quality
  • moderate or severe pain intensity
  • aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)
  • During headache at least one of the following:
  • nausea and/or vomiting
  • photophobia and phonophobia
  • Not attributed to another disorder

排除标准

  • Patients with other light sensitive conditions, such as iritis.
  • Patients who have less than 4 headache days per month
  • Patients who have chronic daily headaches.
  • Patients who have had any change in their migraine treatment within the 4 weeks prior to the trial onset.

结局指标

主要结局

Headache Impact Test (HIT-6) total score

时间窗: Three-week

The primary objective of this study is to evaluate the efficacy of the Avulux device in reducing the impact of migraine headaches as measured by improvement in Headache Impact Test (HIT-6) scores at three weeks when compared to a control/sham device. HIT-6 scores range from 36 to 78. Higher scores indicate a greater impact of headaches on the respondent's life, i.e., 36 = no impact, 78 = maximum impact.

次要结局

  • Number and Severity of Headache Days(Three-week)

研究者

发起方
Avulux, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Optical Treatment of Migraines Using the Avulux™... | 临床试验